X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5537) 5537
Book Review (1731) 1731
Publication (507) 507
Newspaper Article (281) 281
Book Chapter (67) 67
Conference Proceeding (31) 31
Book / eBook (20) 20
Trade Publication Article (7) 7
Dissertation (5) 5
Magazine Article (3) 3
Web Resource (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4475) 4475
humans (4285) 4285
oncology (2076) 2076
male (2031) 2031
neuroendocrine tumors (1951) 1951
female (1731) 1731
middle aged (1509) 1509
cancer (1360) 1360
tumors (1303) 1303
aged (1254) 1254
adult (1088) 1088
neuroendocrine tumors - drug therapy (999) 999
chemotherapy (864) 864
animals (860) 860
metastasis (786) 786
treatment outcome (769) 769
neuroendocrine tumors - pathology (735) 735
endocrinology & metabolism (709) 709
antineoplastic agents - therapeutic use (686) 686
medicine & public health (626) 626
prognosis (618) 618
surgery (594) 594
pancreatic neoplasms - drug therapy (575) 575
care and treatment (503) 503
carcinoma (497) 497
antineoplastic combined chemotherapy protocols - therapeutic use (486) 486
diagnosis (480) 480
expression (475) 475
management (464) 464
survival (461) 461
somatostatin - analogs & derivatives (452) 452
pancreatic neoplasms - pathology (448) 448
aged, 80 and over (447) 447
octreotide (437) 437
patients (431) 431
therapy (431) 431
research (420) 420
cell line, tumor (418) 418
neuroendocrine (401) 401
everolimus (400) 400
liver neoplasms - secondary (396) 396
mice (396) 396
neuroendocrine tumor (393) 393
carcinoma, neuroendocrine - drug therapy (392) 392
abridged index medicus (382) 382
analysis (382) 382
somatostatin (380) 380
health aspects (378) 378
gastroenterology & hepatology (373) 373
immunohistochemistry (372) 372
retrospective studies (372) 372
octreotide - therapeutic use (366) 366
prostate cancer (362) 362
neuroendocrine tumors - therapy (359) 359
cancer therapies (353) 353
carcinoma, neuroendocrine - pathology (336) 336
neuroendocrine tumors - diagnosis (333) 333
neuroendocrine tumors - metabolism (333) 333
pancreas (325) 325
neoplasm staging (324) 324
pharmacology & pharmacy (320) 320
endocrine tumors (315) 315
neuroendocrine differentiation (313) 313
radiology, nuclear medicine & medical imaging (310) 310
phase-ii (303) 303
metastases (301) 301
somatostatin - therapeutic use (301) 301
article (293) 293
pathology (290) 290
prognostic-factors (275) 275
carcinoid (258) 258
peptides (253) 253
disease progression (252) 252
carcinoid-tumors (246) 246
cell biology (246) 246
combined modality therapy (245) 245
drug therapy (245) 245
disease-free survival (240) 240
medicine (239) 239
medical prognosis (237) 237
apoptosis (236) 236
liver (235) 235
mutation (235) 235
neoplasms (235) 235
prostatic neoplasms - pathology (231) 231
survival analysis (228) 228
antineoplastic agents, hormonal - therapeutic use (226) 226
liver metastases (225) 225
neuroendocrine carcinoma (224) 224
lung cancer (222) 222
growth (220) 220
tomography, x-ray computed (220) 220
antineoplastic agents - pharmacology (217) 217
neuroendocrine tumors - genetics (215) 215
review (213) 213
gene expression (211) 211
young adult (211) 211
clinical trials (210) 210
development and progression (210) 210
lung neoplasms - drug therapy (209) 209
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5681) 5681
Japanese (57) 57
German (50) 50
French (46) 46
Italian (17) 17
Spanish (11) 11
Chinese (9) 9
Hungarian (9) 9
Polish (7) 7
Danish (5) 5
Korean (4) 4
Finnish (3) 3
Russian (3) 3
Turkish (2) 2
Croatian (1) 1
Czech (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10022, pp. 968 - 977
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 224 - 233
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 16, pp. 1555 - 1557
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2011, Volume 364, Issue 6, pp. 514 - 523
Journal Article
Science, ISSN 0036-8075, 01/2017, Volume 355, Issue 6320, pp. 78 - 83
Prostate cancer relapsing from antiandrogen therapies can exhibit variant histology with altered lineage marker expression, suggesting that lineage plasticity... 
PATHWAY | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | SMALL-CELL CARCINOMA | PTEN | GENERATION | TUMORIGENESIS | EXPRESSION | DEFICIENCY | DELETION | EZH2 | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Epigenesis, Genetic | Humans | SOXB1 Transcription Factors - antagonists & inhibitors | Male | Retinoblastoma-Like Protein p107 - genetics | Tumor Suppressor Protein p53 - genetics | Neoplasms, Experimental - pathology | Neoplasm Metastasis | Prostatic Neoplasms - genetics | SOXB1 Transcription Factors - genetics | Neoplasms, Experimental - genetics | Adenocarcinoma - genetics | Prostatic Neoplasms - drug therapy | Neuroendocrine Tumors - pathology | PTEN Phosphohydrolase - genetics | Prostatic Neoplasms - pathology | Enhancer of Zeste Homolog 2 Protein - genetics | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Neuroendocrine Tumors - genetics | Cell Lineage | Drug Resistance, Neoplasm - genetics | Animals | Androgen Antagonists - therapeutic use | Cell Line, Tumor | Neuroendocrine Tumors - drug therapy | Cell Plasticity | Mice | Mutation | Neoplasms, Experimental - drug therapy | Prevention | Antimitotic agents | Epigenetic inheritance | Development and progression | Genetic aspects | Dosage and administration | Metastasis | Gene expression | Antineoplastic agents | Drug resistance | Health aspects | Prostate cancer | Drugs | Therapy | Deprivation | Histology | Hormones | Suppressors | Switching | Signal transduction | Sensitivity | Androgens | Inhibitors | Rodents | Plasticity | Epigenetics | Tumor suppressor genes | Plastic properties | Prostate | Cancer | Tumors | Index Medicus | Mutations
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2017, Volume 23, Issue 6, pp. 664 - 673
Neuroendocrine (NE) cancers are a diverse group of neoplasms typically diagnosed and treated on the basis of their site of origin. This Perspective focuses on... 
MOLECULAR CHARACTERIZATION | MEDICINE, RESEARCH & EXPERIMENTAL | PANCREATIC ENDOCRINE NEOPLASMS | TRANSGENIC MOUSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTIANDROGEN RESISTANCE | CONDITIONAL MOUSE MODEL | AURORA KINASE | METASTATIC PROSTATE-CANCER | T-ANTIGEN | CELL BIOLOGY | CELL LUNG-CANCER | N-MYC | Lung Neoplasms - drug therapy | Colonic Neoplasms - genetics | Carcinoma, Small Cell - genetics | Colonic Neoplasms - drug therapy | Epigenesis, Genetic | Humans | Male | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Tumor Suppressor Protein p53 - genetics | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Prostatic Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Female | Cell Differentiation | Retinoblastoma Binding Proteins - genetics | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Triazoles - therapeutic use | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Neuroendocrine - drug therapy | Carcinoma, Small Cell - drug therapy | Carcinogenesis - genetics | Head and Neck Neoplasms - drug therapy | Carcinoma, Neuroendocrine - genetics | Uterine Cervical Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Uterine Cervical Neoplasms - genetics | Disease Progression | Azepines - therapeutic use | Neuroendocrine Tumors - genetics | Proto-Oncogene Proteins c-met - genetics | Cell Lineage | Cell Plasticity - genetics | Esophageal Neoplasms - genetics | Pyrimidines - therapeutic use | Neuroendocrine Tumors - drug therapy | Head and Neck Neoplasms - genetics | Proto-Oncogene Proteins c-myc - genetics | Ubiquitin-Protein Ligases - genetics | Benzodiazepines - therapeutic use | Esophageal Neoplasms - drug therapy | Proteins | Research | Health aspects | Carcinogenesis | Gastrin | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2011, Volume 364, Issue 6, pp. 501 - 513
Journal Article
Science Translational Medicine, ISSN 1946-6234, 08/2015, Volume 7, Issue 302, pp. 302ra136 - 302ra136
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9808, pp. 2005 - 2012
Summary Background Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown antitumour activity in patients with advanced... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | PROGNOSTIC-FACTORS | NEOPLASMS | PATHWAY | PROGRESSION-FREE SURVIVAL | AGENTS | AKT | CANCER-THERAPY | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Double-Blind Method | Carcinoid Tumor - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Octreotide - therapeutic use | Disease Progression | Carcinoid Tumor - pathology | Young Adult | Malignant Carcinoid Syndrome - drug therapy | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Drug Therapy, Combination | Delayed-Action Preparations | Everolimus | Health aspects | Rapamycin | Drug therapy, Combination | Development and progression | Care and treatment | Metastasis | Angiogenesis inhibitors | Analysis | TOR protein | Medical services | Diarrhea | Fatigue | Octreotide | Patients | Survival | Metastases | Anticancer properties | Rank tests | Stomatitis | Randomization | Cell growth | Interactive systems | Pancreas | Drug dosages | Tumors | Neuroendocrine tumors | Clinical medicine | Ovarian cancer | Index Medicus | Abridged Index Medicus | Side effects | fatigue | tumors | Reviews | survival | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article